Novartis' Isturisa (osilodrostat) Receives the US FDA's Approval for Cushing's Disease
Shots:
- The approval is based on a study assessing Isturisa {starting dose of 2mg (bid) that could be increased q2w up to 30mg (bid)} in 137 adults with Cushing’s disease who either had undergone pituitary surgery that did not cure the disease or were not surgical candidates
- The study resulted that half of the patients had cortisol levels within normal limits @24wks. Following the above study- 71 patients entered into 8wks. study assessing Isturisa vs PBO which resulted in maintenance of cortisol level (86% vs 30%)
- Isturisa is the first FDA-approved therapy targeting the cortisol overproduction by blocking the enzyme k/a 11-beta-hydroxylase and preventing cortisol synthesis and has received FDA’s ODD for the same indication
Click here to read full press release/ article
Ref: FDA | Image: Novartis
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com